CytoDyn (CYDY)
(Delayed Data from OTC)
$0.17 USD
+0.01 (9.38%)
Updated Sep 24, 2024 11:42 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
CytoDyn Inc. [CYDY]
Reports for Purchase
Showing records 1 - 20 ( 82 total )
Company: CytoDyn Inc.
Industry: Medical - Drugs
Company: CytoDyn Inc.
Industry: Medical - Drugs
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab Lowers Mortality in Severe or Critical COVID-19; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
COVID-19 Trial Slated to Continue After Interim Analysis; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Emergency Approval for COVID-19 Requires Additional Data; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
FY2020 Financial Results; Positive Phase 2 Data in COVID-19; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Positive Phase 2 Safety Data in COVID-19 Patients; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
NASDAQ Uplisting Application Filed; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab Application for HIV Needs More Data Analysis; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab Prevents Transmission of SHIV in Non-Human Primate Model; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Rich Valuation Amid Rife Competition; Downgrade to Neutral Without PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Phase 2 COVID-19 Data Available Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
FDA to Set Leronlimab Approval Decision Date in HIV Next Month; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Progress in COVID-19 Trials and Beyond; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Biologics License Application Fully Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
HIV Therapy Filing Completed; Leronlimab Decreases COVID-19 Viral Load; Reiterate Buy; Raising PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
First Patient Treated in Pivotal COVID-19 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
Leronlimab Helps More COVID-19 Patients Recover; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
More Severely Ill COVID-19 Patients Treated With Leronlimab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: CytoDyn Inc.
Industry: Medical - Drugs
More Positive COVID-19 Clinical Results; Phase 2 Trials Initiated; Raising PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y